Diosgenin Induces Hypoxia-Inducible Factor-1 Activation and Angiogenesis through Estrogen Receptor-Related Phosphatidylinositol 3-kinase/Akt and p38 Mitogen-Activated Protein Kinase Pathways in Osteoblasts
- 5 July 2005
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 68 (4), 1061-1073
- https://doi.org/10.1124/mol.104.010082
Abstract
Diosgenin, extracted from the root of wild yam (Dioscorea villosa), has been reported to demonstrate an opportunity for medical application. Vascular endothelial growth factor-A (VEGF-A) plays an important role in bone-related angiogenesis, a critical process occurring during bone formation and fracture healing. In this study, we examine whether diosgenin is able to induce VEGF-A expression and to promote angiogenesis in osteoblasts. For murine MC3T3-E1 preosteoblast-like cells, VEGF-A mRNA and protein expression seemed to be significantly elevated in response to diosgenin in a concentration-dependent fashion. Conditioned media prepared from cells treated with diosgenin induced strong angiogenic activity in either in vitro or ex vivo angiogenesis assay. Furthermore, diosgenin treatment increased the stability and activity of HIF-1α protein. Inhibition of HIF-1α activity by transfection with DN-HIF-1α significantly diminished diosgenin-mediated VEGF-A up-regulation. The use of pharmacological inhibitors or genetic inhibition revealed that both the phosphatidylinositol 3-kinase (PI3K)/Akt and p38 signaling pathways were potentially required for diosgenin-induced HIF-1 activation and subsequent VEGF-A up-regulation. It is noteworthy that an estrogen receptor binding assay revealed that diosgenin has the strong ability to replace [3H]estradiol bound to estrogen receptor (IC50, 10 nM). In addition, the specific estrogen receptor antagonists ICI 182,780 (faslodex) and tamoxifen were noted to be able to strongly inhibit diosgenin-induced, src kinase-dependent Akt and p38 MAPK activation. Taken together, such results provide evidence that diosgenin up-regulates VEGF-A and promotes angiogenesis in preosteoblast-like cells by a hypoxia-inducible factor-1α-dependent mechanism involving the activation of src kinase, p38 MAPK, and Akt signaling pathways via estrogen receptor.This publication has 31 references indexed in Scilit:
- 17-β Estradiol Attenuates Hypoxic Induction of HIF-1α and Erythropoietin in Hep3B CellsJournal of Cardiovascular Pharmacology, 2004
- Modelling approaches for angiogenesisEuropean Journal of Cancer, 2004
- Hypoxia-inducible Factor and Its Biomedical RelevancePublished by Elsevier BV ,2003
- Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer CellsJournal of Biological Chemistry, 2002
- Dissecting hypoxia‐dependent and hypoxia‐independent steps in the HIF‐1α activation cascade: implications for HIF‐1α gene therapyThe FASEB Journal, 2001
- Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal womenClimacteric, 2001
- Anabolic Effects of 1,25-Dihydroxyvitamin D3 on Osteoblasts Are Enhanced by Vascular Endothelial Growth Factor Produced by Osteoblasts and by Growth Factors Produced by Endothelial CellsEndocrinology, 1997
- The Biology of Vascular Endothelial Growth FactorEndocrine Reviews, 1997
- Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 12-O-tetradecanoylphorbol-13-acetate and 17β-estradiol on estrogen receptor regulation in MCF-7 human breast cancer cellsJournal of Cellular Biochemistry, 1996
- The Mouse Gene for Vascular Endothelial Growth FactorPublished by Elsevier BV ,1996